Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes

被引：10
|
作者：
Schmid, C. [2 ]
Krayenbuhl, P. [3 ]
Wiesli, P. [1 ]
机构：
[1] Kantonsspital, Med Klin, CH-8500 Frauenfeld, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Internal Med, Med Policlin, Zurich, Switzerland
来源：
DIABETOLOGIA | 2009年 / 52卷 / 12期
关键词：
Hyperinsulinaemia; Insulin dose requirement; Long-acting insulin analogues; Obesity; Type; 2; diabetes; TO-TARGET TRIAL; NPH INSULIN; THERAPY; GLARGINE; DETEMIR;
D O I：
10.1007/s00125-009-1534-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2668 / 2669
页数：2
相关论文
共 50 条
  • [1] Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes
    C. Schmid
    P. Krayenbühl
    P. Wiesli
    [J]. Diabetologia, 2009, 52 : 2668 - 2669
  • [2] The utilisation of long-acting insulin analogues and intermediate-acting insulin in patients with type 2 diabetes in the United Kingdom
    Brunetti, V. C.
    Yu, O. H. Y.
    Platt, R. W.
    Filion, K. B.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S146 - S146
  • [3] Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
    Horvath, K.
    Jeitler, K.
    Berghold, A.
    Ebrahim, S. H.
    Gratzer, T. W.
    Plank, J.
    Kaiser, T.
    Pieber, T. R.
    Siebenhofer, A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02):
  • [4] The effect of long-acting insulin analogues, glargine or detemir, in Type 2 diabetes
    Dissanayake, S.
    Balakrisna-Rao, P.
    Ahmed, A. B.
    [J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [5] Costs Associated With Long-Acting Insulin Analogues in Patients With Diabetes
    Alemayehu, Berhanu
    Speiser, Jessica
    Bloudek, Lisa
    Sarnes, Evelyn
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08): : SP265 - +
  • [6] Cardiovascular mortality in type 2 diabetes patients with incident exposure to long-acting insulin analogues
    Ioacara, S.
    Guja, C.
    Ionescu-Tirgoviste, C.
    Fica, S.
    Reghina, A.
    Georgescu, O.
    Roden, M.
    [J]. DIABETOLOGIA, 2013, 56 : S88 - S88
  • [7] The utilization of long-acting insulin analogues and intermediate-acting NPH insulin among patients with type 2 diabetes in the United Kingdom
    Brunetti, Vanessa C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 404 - 404
  • [8] Long-acting insulin analogues
    Holt, R
    [J]. DIABETES OBESITY & METABOLISM, 2003, 5 (04): : 270 - 270
  • [9] Healthcare costs of fast-acting insulin analogues vs. short-acting human insulin in combination with long-acting insulin analogues for Danish patients with type 2 diabetes
    Gundgaard, J.
    Christensen, T.
    Thomsen, T.
    [J]. DIABETOLOGIA, 2010, 53
  • [10] The Use of Long-Acting Insulin Analogues and the Risk of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana HoiYun
    Azoulay, Laurent
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 52 - 52
12345